Pub Date : 2026-02-01DOI: 10.1016/j.arbres.2025.09.006
Markus Bastir , Francisco García-Río
{"title":"Thoracic Anatomy and Human Evolution: A Respiratory Advantage for Homo sapiens?","authors":"Markus Bastir , Francisco García-Río","doi":"10.1016/j.arbres.2025.09.006","DOIUrl":"10.1016/j.arbres.2025.09.006","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 83-85"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.arbres.2025.10.001
Ana María Alonso Robles , María Jesús Vivancos Gallego , Luis Gorospe Sarasúa
{"title":"Incidental Finding of a Solitary Sternal Plasmacytoma Detected at Lung Cancer Screening With Low-dose CT in a Smoker With HIV Infection","authors":"Ana María Alonso Robles , María Jesús Vivancos Gallego , Luis Gorospe Sarasúa","doi":"10.1016/j.arbres.2025.10.001","DOIUrl":"10.1016/j.arbres.2025.10.001","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 135-136"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145312417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.arbres.2025.10.011
David M.G. Halpin , Refiloe Masekela , Claus F. Vogelmeier , Obianuju B. Ozoh , Alvaro A. Cruz , Helen K. Reddel , Arzu Yorgancıoğlu , Alvar Agusti , on behalf of the Boards of Directors of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global Initiative for Asthma (GINA)
GOLD and GINA have a shared purpose in working to improve outcomes for patients with chronic obstructive pulmonary disease (COPD) and asthma. This joint statement is dedicated to Professor Eric Bateman, an inaugural member of the GINA Science Committee and member of the GINA Board, and to Professor Robert Rodriguez-Roisin, a founder and chair of the GOLD board of directors, both recently deceased. Both made invaluable contributions to asthma and COPD research and took a global perspective on the challenges of diagnosis and management. It was partly Professor Bateman's idea that GOLD and GINA should produce a joint statement addressing the similar challenges faced in the prevention, early and accurate diagnosis and management of both COPD and asthma, emphasizing the determination of both organizations to work together to address these issues.
{"title":"Addressing the Global Challenges of COPD and Asthma: A Shared Vision from the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) and the Global Initiative for Asthma (GINA)","authors":"David M.G. Halpin , Refiloe Masekela , Claus F. Vogelmeier , Obianuju B. Ozoh , Alvaro A. Cruz , Helen K. Reddel , Arzu Yorgancıoğlu , Alvar Agusti , on behalf of the Boards of Directors of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global Initiative for Asthma (GINA)","doi":"10.1016/j.arbres.2025.10.011","DOIUrl":"10.1016/j.arbres.2025.10.011","url":null,"abstract":"<div><div>GOLD and GINA have a shared purpose in working to improve outcomes for patients with chronic obstructive pulmonary disease (COPD) and asthma. This joint statement is dedicated to Professor Eric Bateman, an inaugural member of the GINA Science Committee and member of the GINA Board, and to Professor Robert Rodriguez-Roisin, a founder and chair of the GOLD board of directors, both recently deceased. Both made invaluable contributions to asthma and COPD research and took a global perspective on the challenges of diagnosis and management. It was partly Professor Bateman's idea that GOLD and GINA should produce a joint statement addressing the similar challenges faced in the prevention, early and accurate diagnosis and management of both COPD and asthma, emphasizing the determination of both organizations to work together to address these issues.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 113-117"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146077300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.arbres.2025.08.002
Angela Ramos-Pinedo , Jose Ignacio de Granda-Orive , Maria Isabel Cristóbal-Fernández , Calos Rábade-Castedo , Elia Pérez-Fernández , Paz Vaquero-Lozano , Maria Inmaculada Gorordo-Unzueta , Lourdes Lázaro-Asegurado , Eva de Higes-Martínez , Juan Antonio Riesco-Miranda , Rosa Mirambeaux-Villalona , Gloria Francisco-Corral , Alejandro Frino-García , Jaime Signes-Costa Miñana , Cristina Villar-Laguna , Ana Maria Cicero-Guerrero , Julio Cesar Vargas-Espinal , Teresa Peña-Miguel , Jacobo Sellares , Carlos Andrés Jiménez-Ruiz
Objectives
The main objective was to analyze the short, medium, and long-term effectiveness of a clinical–psychological care protocol for smoking cessation using cytisinicline. Other secondary objectives were evaluate safety and whether the characteristics of smoking, adherence, and the intensity of craving and withdrawal syndrome at 4th week were associated with effectiveness.
Methods
Observational, prospective, multicenter study that includes smokers motivated to quit evaluated in twelve Smoking Cessation Services in Spain.
Results
A total of 337 smokers were studied. Effectiveness of cytisinicline was 68% at the end of treatment, but was reduced to 48.7%, 40.9% and 28.2%, at 3rd, 6th and 12th month of follow up respectively. The measurement of adherence and the intensity of craving by SRC showed statistically significant association with effectiveness at 24th week, RRadj = 2.2 (p < 0.001) and RRadj = 0.87 (p = 0.011) respectively. Common adverse effects (occurring in more than 10% of patients) were: sleep disorders, headaches, dizziness and digestive disorders.
Conclusions
The effectiveness of protocol was 68% at the end of treatment, but was reduced to 48.7%, 40.9% and 28.2% at 3rd, 6th and 12th months respectively. Subjects who met more than 80% of treatment adherence doubled their chances of success at 6th month. For each point of craving intensity, measured by the SRC, at the end of the pharmacological treatment the chances of success at 6th month were reduced by 13%. Cytisinicline was safe.
{"title":"Analysis of Effectiveness of Clinical Psychological Care Protocol for Smoking Cessation With Cytisinicline","authors":"Angela Ramos-Pinedo , Jose Ignacio de Granda-Orive , Maria Isabel Cristóbal-Fernández , Calos Rábade-Castedo , Elia Pérez-Fernández , Paz Vaquero-Lozano , Maria Inmaculada Gorordo-Unzueta , Lourdes Lázaro-Asegurado , Eva de Higes-Martínez , Juan Antonio Riesco-Miranda , Rosa Mirambeaux-Villalona , Gloria Francisco-Corral , Alejandro Frino-García , Jaime Signes-Costa Miñana , Cristina Villar-Laguna , Ana Maria Cicero-Guerrero , Julio Cesar Vargas-Espinal , Teresa Peña-Miguel , Jacobo Sellares , Carlos Andrés Jiménez-Ruiz","doi":"10.1016/j.arbres.2025.08.002","DOIUrl":"10.1016/j.arbres.2025.08.002","url":null,"abstract":"<div><h3>Objectives</h3><div>The main objective was to analyze the short, medium, and long-term effectiveness of a clinical–psychological care protocol for smoking cessation using cytisinicline. Other secondary objectives were evaluate safety and whether the characteristics of smoking, adherence, and the intensity of craving and withdrawal syndrome at 4th week were associated with effectiveness.</div></div><div><h3>Methods</h3><div>Observational, prospective, multicenter study that includes smokers motivated to quit evaluated in twelve Smoking Cessation Services in Spain.</div></div><div><h3>Results</h3><div>A total of 337 smokers were studied. Effectiveness of cytisinicline was 68% at the end of treatment, but was reduced to 48.7%, 40.9% and 28.2%, at 3rd, 6th and 12th month of follow up respectively. The measurement of adherence and the intensity of craving by SRC showed statistically significant association with effectiveness at 24th week, RRadj<!--> <!-->=<!--> <!-->2.2 (<em>p</em> <!--><<!--> <!-->0.001) and RRadj<!--> <!-->=<!--> <!-->0.87 (<em>p</em> <!-->=<!--> <!-->0.011) respectively. Common adverse effects (occurring in more than 10% of patients) were: sleep disorders, headaches, dizziness and digestive disorders.</div></div><div><h3>Conclusions</h3><div>The effectiveness of protocol was 68% at the end of treatment, but was reduced to 48.7%, 40.9% and 28.2% at 3rd, 6th and 12th months respectively. Subjects who met more than 80% of treatment adherence doubled their chances of success at 6th month. For each point of craving intensity, measured by the SRC, at the end of the pharmacological treatment the chances of success at 6th month were reduced by 13%. Cytisinicline was safe.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 94-103"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.arbres.2025.09.002
Pamela J. McShane
{"title":"Are Dipeptidyl Peptidase-1 Inhibitors the Future Anti-inflammatory Treatment in Bronchiectasis?","authors":"Pamela J. McShane","doi":"10.1016/j.arbres.2025.09.002","DOIUrl":"10.1016/j.arbres.2025.09.002","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 78-79"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145430227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.arbres.2025.09.001
Irina González
{"title":"The Harms of Vaping: How Clinicians Can Help Patients Quit","authors":"Irina González","doi":"10.1016/j.arbres.2025.09.001","DOIUrl":"10.1016/j.arbres.2025.09.001","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 75-77"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.arbres.2025.09.021
João Faria Dias , Mariana Borges Dias , Gustavo Rocha
Congenital lung malformations (CLMs) encompass a range of developmental anomalies, including congenital pulmonary airway malformation (CPAM), bronchopulmonary sequestration (BPS), congenital lobar overinflation (CLO), bronchogenic cysts (BC), and bronchial atresia (BA). These lesions present with varying severity, from incidental findings to severe neonatal respiratory distress. Advances in prenatal imaging, such as ultrasound and fetal magnetic resonance image (MRI), have significantly improved early detection, aiding in better management planning.
CLMs arise from abnormalities during specific stages of lung development. CPAMs are categorized by cyst size and histological type, while BPS is characterized by systemic arterial supply. CLO and BA are associated with air trapping and hyperinflation, and BCs are typically fluid-filled, well defined, and compressive. Postnatal diagnosis is based on high-resolution computed tomography (CT) and occasionally MRI for detailed evaluation.
Surgical resection is recommended for symptomatic lesions, while management of asymptomatic cases remains debated. Elective surgery may help prevent complications like infection or rare malignancy, particularly in CPAM Types 1 and 4 and BCs. However, some lesions remain stable or regress, supporting conservative management in selected cases.
Long-term outcomes are generally positive, with children undergoing early resection often maintaining good lung function due to compensatory lung growth, though subtle functional deficits may persist. Risk stratification using imaging and genetic markers, such as DICER1 mutations, is gaining importance for guiding treatment decisions.
Management should be individualized, involving a multidisciplinary approach and shared decision-making with families. Further research is needed to clarify the natural history of CLMs, optimize the timing of interventions, and standardize long-term surveillance strategies.
{"title":"Congenital Lung Malformations: A Comprehensive Overview of Current Knowledge—Narrative Review","authors":"João Faria Dias , Mariana Borges Dias , Gustavo Rocha","doi":"10.1016/j.arbres.2025.09.021","DOIUrl":"10.1016/j.arbres.2025.09.021","url":null,"abstract":"<div><div>Congenital lung malformations (CLMs) encompass a range of developmental anomalies, including congenital pulmonary airway malformation (CPAM), bronchopulmonary sequestration (BPS), congenital lobar overinflation (CLO), bronchogenic cysts (BC), and bronchial atresia (BA). These lesions present with varying severity, from incidental findings to severe neonatal respiratory distress. Advances in prenatal imaging, such as ultrasound and fetal magnetic resonance image (MRI), have significantly improved early detection, aiding in better management planning.</div><div>CLMs arise from abnormalities during specific stages of lung development. CPAMs are categorized by cyst size and histological type, while BPS is characterized by systemic arterial supply. CLO and BA are associated with air trapping and hyperinflation, and BCs are typically fluid-filled, well defined, and compressive. Postnatal diagnosis is based on high-resolution computed tomography (CT) and occasionally MRI for detailed evaluation.</div><div>Surgical resection is recommended for symptomatic lesions, while management of asymptomatic cases remains debated. Elective surgery may help prevent complications like infection or rare malignancy, particularly in CPAM Types 1 and 4 and BCs. However, some lesions remain stable or regress, supporting conservative management in selected cases.</div><div>Long-term outcomes are generally positive, with children undergoing early resection often maintaining good lung function due to compensatory lung growth, though subtle functional deficits may persist. Risk stratification using imaging and genetic markers, such as <em>DICER1</em> mutations, is gaining importance for guiding treatment decisions.</div><div>Management should be individualized, involving a multidisciplinary approach and shared decision-making with families. Further research is needed to clarify the natural history of CLMs, optimize the timing of interventions, and standardize long-term surveillance strategies.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"62 2","pages":"Pages 104-112"},"PeriodicalIF":9.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号